Cantargia (OMX: CANTA)

Last close As at 27/03/2024

SEK2.92

0.06 (2.10%)

Market capitalisation

SEK537m

Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Increasing understanding of inflammation in malignant processes suggests that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to evade immune responses. Therefore, cytokines represent a potentially promising class of targets in oncology.

Latest Insights

View More

Healthcare | Flash note

Cantargia — Encouraging data for nadunolimab in CANFOUR

Healthcare | Flash note

Cantargia — First patient treated in Phase II part of TRIFOUR

Healthcare | Update

Cantargia — Next phase of clinical development in sight

Healthcare | Update

Cantargia — Strong momentum in first nine months of FY22

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Key Management

  • Goran Forsberg

    CEO

Balance Sheet

Forecast net debt (SEKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (4.7) (24.7) (54.9)
Relative (9.9) (30.8) (63.4)
52 week high/low SEK7.3/SEK2.6

Financials

Cantargia is developing antibodies against IL1RAP. Interim data from CANFOUR (Phase Ib/IIa) in NSCLC and pancreatic ductal adenocarcinoma (PDAC) suggest that nadunolimab could have synergistic benefit with chemotherapy or ADCs. Supportive clinical/biomarker data for PDAC was recently reported and the company is now preparing for a Phase IIb trial in PDAC. Further, Cantargia recently shared positive interim data from TRIFOUR (Phase Ib portion), assessing nadunolimab in triple-negative breast cancer; the Phase II portion is ongoing. Cantargia also announced a $1.1m grant to support a new Phase Ib/IIa clinical trial for nadunolimab in leukaemia. A second programme, CAN10, is being developed for the treatment of autoimmune diseases. Encouraging initial data from the dose-escalation stage was shared in January 2024. At end-Q323, Cantargia had c SEK200m in cash and short-term investments, bolstered by a SEK59m raise in October 2023.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2022A 0.0 (377.9) (371.8) (290.43) N/A N/A
2023A 0.0 (286.6) (280.0) (164.94) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free